Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Chin J Integr Med ; 30(3): 222-229, 2024 Mar.
Article de Anglais | MEDLINE | ID: mdl-37597119

RÉSUMÉ

OBJECTIVE: To determine the role of Tripterygium wilfordii multiglycoside (TGW) in the treatment of psoriatic dermatitis from a cellular immunological perspective. METHODS: Mouse models of psoriatic dermatitis were established by imiquimod (IMQ). Twelve male BALB/c mice were assigned to IMQ or IMQ+TGW groups according to a random number table. Histopathological changes in vivo were assessed by hematoxylin and eosin staining. Ratios of immune cells and cytokines in mice, as well as PAM212 cell proliferation in vitro were assessed by flow cytometry. Pro-inflammatory cytokine expression was determined using reverse transcription quantitative polymerase chain reaction. RESULTS: TGW significantly ameliorated the severity of IMQ-induced psoriasis-like mouse skin lesions and restrained the activation of CD45+ cells, neutrophils and T lymphocytes (all P<0.01). Moreover, TGW significantly attenuated keratinocytes (KCs) proliferation and downregulated the mRNA levels of inflammatory cytokines including interleukin (IL)-17A, IL-23, tumor necrosis factor α, and chemokine (C-X-C motif) ligand 1 (P<0.01 or P<0.05). Furthermore, it reduced the number of γ δ T17 cells in skin lesion of mice and draining lymph nodes (P<0.01). CONCLUSIONS: TGW improved psoriasis-like inflammation by inhibiting KCs proliferation, as well as the associated immune cells and cytokine expression. It inhibited IL-17 secretion from γ δ T cells, which improved the immune-inflammatory microenvironment of psoriasis.


Sujet(s)
Dermatite , Psoriasis , Maladies de la peau , Mâle , Animaux , Souris , Tripterygium , Psoriasis/traitement médicamenteux , Kératinocytes , Maladies de la peau/métabolisme , Cytokines/métabolisme , Imiquimod/effets indésirables , Imiquimod/métabolisme , Dermatite/métabolisme , Dermatite/anatomopathologie , Modèles animaux de maladie humaine , Souris de lignée BALB C , Peau/métabolisme
2.
Inorg Chem ; 61(28): 10774-10780, 2022 Jul 18.
Article de Anglais | MEDLINE | ID: mdl-35796528

RÉSUMÉ

HIV-1 reverse transcriptase (RT) inhibitors are fundamental to the discovery and development of anti-HIV drugs. Their main target is RT, and only a tiny number of them can bind to viral RNA. In this paper, five new Zn(II) porphyrin compounds were developed with different characters. ZnTPP4 has both the appearance and the functions of a scorpion with a rigid tail and stinger to selectively hunt HIV-1 TAR RNA based on the molecular recognition of hydrogen bonds, a fierce chelicera to bite RNA by metal coordination, mighty pedipalps to grasp the bound RNA by supramolecular inclusion, and a broad body maintaining the configuration of each functional area so that they can cooperate with each other and providing accommodation space for the bound RNA. This tetrafunctional Zn(II) porphyrin is relatively nontoxic to normal cells and can produce sensitive responses for RNA. Moreover, this work offers practical construction methodologies for medication of AIDS and other diseases closely related to RT like EBOV and SARS-CoV-2.


Sujet(s)
COVID-19 , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Métalloporphyrines , Inhibiteurs de la transcriptase inverse , Transcriptase inverse du VIH/antagonistes et inhibiteurs , Humains , Métalloporphyrines/pharmacologie , ARN viral , Inhibiteurs de la transcriptase inverse/composition chimique , Inhibiteurs de la transcriptase inverse/pharmacologie , SARS-CoV-2
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE